Background: Multisystem inflammatory syndrome in children (MIS-C) is a condition where different body parts can become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs. There is persistent fever along with inflammation, which can lead to medical emergencies and neonates and children may require critical care. Aims and objectives: This study evaluates use of pulse therapy of methyl prednisolone versus prednisolone and intravenous immunoglobulin (IVIG) in multisystem inflammatory syndrome in children (MISC). Methodology: This analytical study was carried out in 30 children with history of SARS-CoV-19 or MISC attending the PICU or NICU of the Tertiary care centre of DVVPF’s Medical College, Ahmednagar. The study was carried out from January 2021 to December 2021. Results: Total of 30 patients were studied with male majority (60%), and mean age of 7.35 years. 28 were kept in the ICU (93.33%). GI symptoms were seen in 24 cases (80%), Mucocutaneous manifestation in 25 cases (83.33%), Multiorgan involvement (>3 organs) in 23 cases (76.67%). D Dimer was raised in 29 cases (96.67%), Thrombocytopenia was seen in 24 cases (80%). CNS involvement in 14 cases (46.67%) with headaches in 7 (23.33%), encephalopathy in 5 cases (16.67%) and seizures in 4 cases (13.33%). Respiratory system involvement was seen in 16 cases (53.33%). We observed that the outcome characteristic features were better in the Methylprednisolone pulse therapy plus IVIG group. (p<0.05) Out of 15 patients in the two groups, 3 patients died in Methylprednisolone pulse therapy group (20%) while there was one death in the Methylprednisolone pulse therapy plus IVIG group. Significant difference was seen in the survival of the two groups. (p = 0.04). Conclusion: There is improvement in both the groups which received the treatment with either Methylprednisolone pulse therapy or Methylprednisolone pulse therapy plus IVIG. Comparatively there was less ICU stay, less complications and better patient survival in Methylprednisolone pulse therapy plus IVIG group.
Ciotti M, Ciccozzi M, Terrinoni A, Jiang WC, Wang CB, Bernardini S. The COVID-19 pandemic. Critical reviews in clinical laboratory sciences. 2020 Aug 17;57(6):365-88.
Kaushal V, Srivastava S. Hospitality and tourism industry amid COVID-19 pandemic: Perspectives on challenges and learnings from India. International journal of hospitality management. 2021 Jan 1;92:102707.
Unni JC. Social effects of Covid-19 pandemic on children in India. Indian Journal of Practical Pediatrics. 2020;22(2):102-4.
Jain S, Sen S, Lakshmivenkateshiah S, Bobhate P, Venkatesh S, Udani S, Shobhavat L, Andankar P, Karande T, Kulkarni S. Multisystem inflammatory syndrome in children with COVID-19 in Mumbai, India. Indian pediatrics. 2020 Nov;57(11):1015-9.
Gupta Dch S, Chopra Md N, Singh Md A, Gera R, Chellani Md H, Pandey PhD R, Arora Md BS. Unusual clinical manifestations and outcome of multisystem inflammatory syndrome in children (MIS-C) in a tertiary care hospital of North India. Journal of Tropical Pediatrics. 2021 Feb;67(1):fmaa127.
Shah SK, Munoz AC. Multisystem inflammatory syndrome in children in COVID-19 pandemic. The Indian Journal of Pediatrics. 2020 Sep;87(9):671-3.
Mirrahimi AS, Tabatabaei SR. An Algorithmic Approach to Management of COVID-19 Associated Multisystem Inflammatory Syndrome in Children. Arch Pediatr. 2021 Jan;9(1):e110479.
Greene AG, Saleh M, Roseman E, Sinert R. Toxic shock-like syndrome and COVID-19: Multisystem inflammatory syndrome in children (MIS-C). The American journal of emergency medicine. 2020 Nov 1;38(11):2492-e5.
Tiwari A, Balan S, Rauf A, Kappanayil M, Kesavan S, Raj M, Sivadas S, Vasudevan AK, Chickermane P, Vijayan A, John ST. COVID-19 related multisystem inflammatory syndrome in children (MIS-C): a hospital-based prospective cohort study from Kerala, India. BMJ paediatrics open. 2021;5(1).
Sai BV, Kumar H, Arun Babu T, Chaitra R, Satapathy D, Kalidoss VK. Clinical Spectrum of Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 Infection. Indian Journal of Pediatrics. 2022 Jan 30:1-.
Aslan N, Yildizdas D, Sinanoglu MS. A pediatric COVID19 case with suspected acute abdomen, hyperferritinemic sepsis and developing MIS-C and pancreatitis. The Indian Journal of Pediatrics. 2021 Mar;88(3):288-.
Sarkar M, Pal P, Raychaudhuri D, Sen B, Roychowdhoury S, Chattopadhyay A, Hazra A, Mondal R. PIMS-TS vs. MIS-C: Diagnostic Criteria in COVID-19–Associated Hyperinflammation in Children. Indian Journal of Pediatrics. 2021 Nov;88(11):1149-50.
Sugunan S, Bindusha S, Geetha S, Niyas HR, Kumar AS. Clinical profile and short-term outcome of children with SARS-CoV-2 related multisystem inflammatory syndrome (MIS-C) treated with pulse methylprednisolone. Indian Pediatrics. 2021 Aug;58(8):718-22.
Bhat CS, Gupta L, Balasubramanian S, et al. Hyperinflammatory syndrome in children associated with COVID-19: Need for awareness. Indian Pediatr. 2020;57:929-35.
Nakra NA, Blumberg DA, Herrera-Guerra A, et al. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: Review of clinical presentation, hypothetical pathogenesis, and proposed management. Children (Basel). 2020;7:E69.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2022 Dr. Sneha Mhaske, Dr. S. N. Mhaske, Dr. Ganesh Misal, Dr. Abhijit Shinde, Dr. Suresh Waydande